USA flag logo/image

An Official Website of the United States Government

AIT-082; A DRUG FOR TREATMENT OF ALZHEIMER'S DISEASE

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
16260
Program Year/Program:
1993 / SBIR
Agency Tracking Number:
16260
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Advanced Immunotherapeutics
2691 Richter Avenue, Suite 105 Irvine, CA 92714
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1993
Title: AIT-082; A DRUG FOR TREATMENT OF ALZHEIMER'S DISEASE
Agency: HHS
Contract: N/A
Award Amount: $478,811.00
 

Abstract:

WE WILL DEVELOP AIT-082 FOR THE TREATMENT OF DEMENTIA DUE TO ALZHEIMER'S DISEASE, STROKE OR AGING. IN PHASE I, WE PLAN TO COMPLETE THE PRECLINICAL STUDIES NEEDED TO SUBMIT AN INVESTIGATION- AL NEW DRUG (IND) EXEMPTION APPLICATION TO THE FOOD AND DRUG ADMINISTRATION (FDA). SPECIFICALLY, WE WILL: (1) DETERMINE THE PRECLINICAL PHARMACODYNAMICS/ PHARMACOKINETICS OF AIT-082, (2) CONDUCT PRECLINICAL TOXICOLOGICAL TESTING, AND (3) CONDUCT ADDITIONAL PRECLINICAL STUDIES ON THE MECHANISM OF ACTION OF AIT- 082. THE AIM OF PHASE II WILL BE TO FILE AN IND APPLICATION AND TO ESTABLISH THE CLINICAL SAFETY AND EFFICACY OF AIT-082.

Principal Investigator:

Glasky, Alvin J
Principal Investigator
7147562230

Business Contact:

1 r43 ag09911-01
Small Business Information at Submission:

Advanced Immunotherapeutics
2691 Richter Avenue, Suite 105 Irvine, CA 92714

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No